<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298922</url>
  </required_header>
  <id_info>
    <org_study_id>AZ 0003</org_study_id>
    <secondary_id>TULLIS04A0</secondary_id>
    <nct_id>NCT00298922</nct_id>
  </id_info>
  <brief_title>Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex</brief_title>
  <official_title>Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Azithromycin in Patients With CF, Chronically Infected With Burkholderia Cepacia Complex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary infection with Burkholderia cepacia complex (BCC) in patients with CF is often&#xD;
      associated with a more rapid decline in lung function. Because of the resistance of BCC to&#xD;
      many antibiotics, treatment options are often limited. New therapies to improve outcomes for&#xD;
      patients infected with BCC are needed.&#xD;
&#xD;
      However, because of the unpredictable nature of this pulmonary infection in CF, patients with&#xD;
      BCC infection have been excluded from many CF therapeutic trials.&#xD;
&#xD;
      Recent published trials in the United States, Australia, and the United Kingdom have all&#xD;
      demonstrated clinical benefits from prolonged administration of azithromycin in CF. In these&#xD;
      trials, the vast majority of patients were chronically infected with Pseudomonas aeruginosa.&#xD;
&#xD;
      Patients with BCC were excluded from the US and UK trials, and only four patients with BCC&#xD;
      infection were enrolled in the Australian trial. Thus, the effectiveness of azithromycin in&#xD;
      CF patients infected with BCC is largely unknown and deserves further study.&#xD;
&#xD;
      The two main ways by which azithromycin is thought to help with the chronic lung infections&#xD;
      seen in CF are by [a] reducing inflammation and [b] direct effects on the bacteria, in&#xD;
      particular P. aeruginosa. BCC pulmonary infection in CF is often associated with a large&#xD;
      inflammatory response similar to or more severe than P. aeruginosa infection. If azithromycin&#xD;
      works mainly by an anti-inflammatory mechanism, it should also be helpful in CF patients&#xD;
      infected with BCC.&#xD;
&#xD;
      Alternatively, azithromycin could have a direct effect on BCC as seen with P. aeruginosa as&#xD;
      the two bacteria have many similarities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN&#xD;
&#xD;
        -  Overview&#xD;
&#xD;
        -  This is a single center, randomized, double-blinded, placebo-controlled 24 week trial of&#xD;
           azithromycin in adults with CF chronically infected with BCC. The investigational&#xD;
           therapy will be added to usual therapy in patients who are clinically stable at the time&#xD;
           of enrollment. After 168 days, the study drug will be discontinued and participants will&#xD;
           be evaluated at 196 days off of study drug for 28 days. At that visit, participants will&#xD;
           be invited to continue in an open label observational study of azithromycin for 168&#xD;
           additional days. Thus, the duration of the study will be 52 weeks (364 days).&#xD;
&#xD;
        -  Day 0- Day 168 on Study Drug (24 weeks)&#xD;
&#xD;
        -  Day 169- Day 196 off Study Drug (4 weeks)&#xD;
&#xD;
        -  Day 197 - Day 364 on OPEN label Azithromycin (24 weeks)&#xD;
&#xD;
        -  Measuring primary and secondary endpoints&#xD;
&#xD;
        -  Primary efficacy endpoint&#xD;
&#xD;
        -  Primary efficacy endpoint will be the quantitative changes in lung function as measured&#xD;
           by FEV1 in % predicted from baseline to completion of the 24 week treatment period.&#xD;
           (refer to Appendix C for ATS guidelines).&#xD;
&#xD;
        -  Primary safety endpoints&#xD;
&#xD;
        -  Primary safety endpoints collected over the 24 week treatment period will be:&#xD;
&#xD;
             -  Adverse events such as gastrointestinal complaints, ototoxicity, tinnitus,&#xD;
                hepatitis or leukopenia as determined by:&#xD;
&#xD;
                (i) open ended questioning of study subjects at study visits (ii) laboratory tests&#xD;
                for elevated liver function tests or hematologic abnormalities,&#xD;
&#xD;
             -  Changes in lung microbiology as determined by:[86] (i) Emergent B. cenocepacia&#xD;
                (genomovar III) (ii) Emergent non-B. cenocepacia genomovars (iii) Emergent NTM[87]&#xD;
                (iv) Emergent azithromycin resistant NTM (v) Emergent Aspergillus species (vi)&#xD;
                Emergent MDRO - (S. maltophilia, A. xylosoxidans, or methicillin-resistant S.&#xD;
                aureus) (vii) Emergent P. aeruginosa (viii) Emergent azithromycin resistant S.&#xD;
                aureus&#xD;
&#xD;
        -  Secondary efficacy endpoints&#xD;
&#xD;
        -  Secondary efficacy endpoints will be:&#xD;
&#xD;
        -  Quantitative changes in lung function as measured by change in relative percent change&#xD;
           in FEV1 and FVC from baseline to completion of the 24 week treatment period.&#xD;
&#xD;
        -  Quantitative change in FEV1 and FVC in liters in CF study subjects treated with&#xD;
           azithromycin compared with those CF study subjects treated with placebo. FEV1 and FVC in&#xD;
           liters will be measured according to ATS criteria&#xD;
&#xD;
        -  The number of days until first administration of intravenous antibiotics and/or the use&#xD;
           of oral tetracycline derivatives minocycline / doxycycline for seven or more days during&#xD;
           the 24 week period.&#xD;
&#xD;
        -  The number of pulmonary exacerbations as defined by need for treatment with intravenous&#xD;
           or oral tetracycline derivative antibiotics for an increase in pulmonary symptoms during&#xD;
           the 24 week period.&#xD;
&#xD;
        -  The proportion of patients requiring intravenous antibiotics during the 24 week period.&#xD;
&#xD;
        -  The number of days of treatment with intravenous antibiotics given during the 24 week&#xD;
           period.&#xD;
&#xD;
        -  The proportion of patients hospitalized.&#xD;
&#xD;
        -  The number of hospital days as calculated by calendar days during the 24 week period.&#xD;
&#xD;
        -  The proportion of patients requiring oral antibiotics during the 24 week period.&#xD;
&#xD;
        -  The number of days of treatment with oral non-tetracycline derivative antibiotics given&#xD;
           during the 24 week period.&#xD;
&#xD;
        -  Changes in body weight from baseline to completion of the 24 week treatment period.&#xD;
&#xD;
        -  Change in level of inflammation as measured by the change in serum CRP and ESR from&#xD;
           baseline to the end of the 24 week treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2006</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Anticipated">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1 in % predicted in CF study subjects treated with azithromycin compared with those CF study subjects treated with placebo.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants taking 500 mg tablets orally thrice weekly for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants taking 500 mg tablets orally thrice weekly for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>500 mg tablets orally thrice weekly for 24 weeks</description>
    <arm_group_label>Azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet orally thrice weekly for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent and verbal assent as appropriate has been provided by the subject&#xD;
&#xD;
          -  Ability to comply with medication use, study visits and study procedures as judged by&#xD;
             the site Investigator&#xD;
&#xD;
          -  Diagnosis of CF as defined by two or more clinical features of CF and a documented&#xD;
             sweat chloride &gt; 60 mEq/L by quantitative pilocarpine iontophoresis test or a genotype&#xD;
             showing two well characterized disease causing mutations&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  Body weight &gt; 40 kg&#xD;
&#xD;
          -  BCC present in a sputum/throat culture &gt; 1 year prior to screening and at screening&#xD;
&#xD;
          -  FEV1 % predicted &gt; 30% as calculated by the Knudsen reference equations&#xD;
&#xD;
          -  Room air oximetry &gt; 88% at rest&#xD;
&#xD;
          -  Post-menarche females must be surgically sterile or using an effective form of&#xD;
             contraception&#xD;
&#xD;
          -  Predicted to live &gt; 1 year and clinically stable at that time of enrollment as judged&#xD;
             by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of chronic macrolide use, defined as regular macrolide antibiotic use within a&#xD;
             three month period prior to enrollment in the study.&#xD;
&#xD;
          -  AST or ALT &gt; 2.5 times the upper limit of normal performed at the local laboratories&#xD;
             on two occasions prior to randomization.&#xD;
&#xD;
          -  Investigational drug use within 30 days of screening&#xD;
&#xD;
          -  History of alcohol, illicit drug or medication abuse within 1 year of screening&#xD;
&#xD;
          -  Use of intravenous antibiotics or oral antibiotics within 14 days of screening.&#xD;
&#xD;
          -  Use of low dose oral antibiotics (e.g. macrolides, tetracycline, sulfa) for acne or&#xD;
             other conditions within 30 days of screening&#xD;
&#xD;
          -  Use of systemic corticosteroids (&gt; 20 mg of prednisone per day) within 30 days of&#xD;
             screening&#xD;
&#xD;
          -  Initiation of TOBIÂ®, high dose ibuprofen, or rhDNase within 60 days of screening&#xD;
&#xD;
          -  History of lung transplantation or currently on lung transplant list&#xD;
&#xD;
          -  History of allergy to a macrolide antibiotic&#xD;
&#xD;
          -  AFB smear positive at screening suggesting current NTM infection.&#xD;
&#xD;
          -  Positive serum pregnancy test at screening (to be performed on all post-menarche&#xD;
             females)&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 1000 performed at the local laboratories on two occasions&#xD;
             prior to randomization&#xD;
&#xD;
          -  Creatinine &gt; 1.5 times normal performed at the local laboratories on two occasions&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Chest x-ray changes or physical findings at screening that would compromise the safety&#xD;
             of the patient or the quality of the study data&#xD;
&#xD;
          -  Other major organ dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Tullis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>March 2, 2006</study_first_submitted>
  <study_first_submitted_qc>March 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2006</study_first_posted>
  <last_update_submitted>July 30, 2009</last_update_submitted>
  <last_update_submitted_qc>July 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Elizabeth Tullis</name_title>
    <organization>St. Michael's Hospital</organization>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Burkholderia cepacia complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

